In last trading session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) saw 0.31 million shares changing hands with its beta currently measuring 2.68. Company’s recent per share price level of $4.11 trading at -$0.17 or -3.97% at ring of the bell on the day assigns it a market valuation of $190.30M. That closing price of FDMT’s stock is at a discount of -782.0% from its 52-week high price of $36.25 and is indicating a premium of 9.25% from its 52-week low price of $3.73. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.74 million shares which gives us an average trading volume of 936.62K if we extend that period to 3-months.
For 4D Molecular Therapeutics Inc (FDMT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.75. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Upright in the red during last session for losing -3.97%, in the last five days FDMT remained trading in the green while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $4.11 price level, adding 7.43% to its value on the day. 4D Molecular Therapeutics Inc’s shares saw a change of -26.21% in year-to-date performance and have moved 0.98% in past 5-day. 4D Molecular Therapeutics Inc (NASDAQ:FDMT) showed a performance of -9.67% in past 30-days. Number of shares sold short was 5.24 million shares which calculate 5.58 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 37.5 to the stock, which implies a rise of 89.04% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 40. It follows that stock’s current price would drop -45.99% in reaching the projected high whereas dropping to the targeted low would mean a loss of -45.99% for stock’s current value.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.89% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -18.70% while estimates for its earnings growth in next 5 years are of -4.47%.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
Insiders are in possession of 3.91% of company’s total shares while institution are holding 103.21 percent of that, with stock having share float percentage of 107.40%. Investors also watch the number of corporate investors in a company very closely, which is 103.21% institutions for 4D Molecular Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at FDMT for having 4.9 million shares of worth $102.79 million. And as of 2024-06-30, it was holding 9.9385 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 5.1 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2221 of outstanding shares, having a total worth of $107.01 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.54 shares of worth $6.32 million or 3.32% of the total outstanding shares. The later fund manager was in possession of 1.37 shares on Dec 31, 2024 , making its stake of worth around $5.64 million in the company or a holder of 2.97% of company’s stock.
